Another study in patients with hematological cancer and COVID-19 revealed that 77% had detectable SARS-CoV-2-specific T-cell responses despite impaired humoral immunity, including those treated with anti-CD20 therapy, and those with several CD8+ T cells had improved survival [26]. This evidence concerns the gene CD8A and COVID-19.